<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975010</url>
  </required_header>
  <id_info>
    <org_study_id>BUP14-CN-101</org_study_id>
    <nct_id>NCT03975010</nct_id>
  </id_info>
  <brief_title>Buprenorphine Transdermal Patches Pharmacokinetic Study</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, Parallel-group Study to Investigate the PK Profile of Single Dose Buprenorphine Transdermal Patch 20 mg Applied for 3 Days, 40 mg for 3 Days and 40 mg for 4 Days in Chinese Subjects With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma (China) Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma (China) Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomised, single-dose, 3 arms study design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3&#xD;
      days or 40 mg for 3 days or 40 mg for 4 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profile of buprenorphine and its primary metabolite, norbuprenorphine_Cmax</measure>
    <time_frame>from Day0 to Day8 or Day9</time_frame>
    <description>Pharmacokinetic parameters of the prototype buprenorphine, and the primetabolite norbuprenorphine, calculated from plasma concentration-time data following a single application of BUP TDS 20 mg (3 days), 40 mg (3 days) and 40 mg (4 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profile of buprenorphine and its primary metabolite, norbuprenorphine_AUCt</measure>
    <time_frame>from Day0 to Day8 or Day9</time_frame>
    <description>Pharmacokinetic parameters of the prototype buprenorphine, and the primetabolite norbuprenorphine, calculated from plasma concentration-time data following a single application of BUP TDS 20 mg (3 days), 40 mg (3 days) and 40 mg (4 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetic profile of buprenorphine and its primary metabolite, norbuprenorphine_AUCinf</measure>
    <time_frame>from Day0 to Day8 or Day9</time_frame>
    <description>Pharmacokinetic parameters of the prototype buprenorphine, and the primetabolite norbuprenorphine, calculated from plasma concentration-time data following a single application of BUP TDS 20 mg (3 days), 40 mg (3 days) and 40 mg (4 days).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>BUP TDS 20 mg for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUP TDS 40 mg for 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUP TDS 40 mg for 4 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine Transdermal Patch</intervention_name>
    <description>This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7~9 days after patch removal.&#xD;
The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.</description>
    <arm_group_label>BUP TDS 20 mg for 3 days</arm_group_label>
    <arm_group_label>BUP TDS 40 mg for 3 days</arm_group_label>
    <arm_group_label>BUP TDS 40 mg for 4 day</arm_group_label>
    <other_name>Naltrexone Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese male or female subjects with chronic pain (regardless of the aetiology,&#xD;
             cancer-pain excluded), aged 18-55 years (both inclusive).&#xD;
&#xD;
          -  The average pain over the last 24 hours should attain ≤ 3 assessed with Numeric Rating&#xD;
             Scales (NRS) refer to section 19.5. The pain condition has been lasting for at least 1&#xD;
             month and stable for 7 days prior to entering into the screening and is expected to be&#xD;
             stable during the study duration.&#xD;
&#xD;
          -  Patients on stable permissible non-opioid analgesics, who in the opinion of the&#xD;
             investigator are unlikely to require a change in treatment during the study.&#xD;
&#xD;
          -  Karnofsky score of Performance Status ≥ 70.&#xD;
&#xD;
          -  Body mass index (BMI) of 19 to 28 kg/m2 (both inclusive); and a total body weight ≥ 50&#xD;
             kg.&#xD;
&#xD;
          -  Normal dietary habits (e.g. not vegetarian nor vegan) and willing to only take the&#xD;
             food supplied during the period of hospitalization.&#xD;
&#xD;
          -  Subjects who are able to read, understand and sign written informed consent prior to&#xD;
             study participation and are willing to follow the protocol requirements.&#xD;
&#xD;
          -  Female subjects of child bearing potential (less than 1 year post-menopausal) must&#xD;
             have a negative urine pregnancy test prior to first dose of study medication, be&#xD;
             non-lactating, and willing to use adequate and highly effective methods of birth&#xD;
             control throughout the study such as sterilisation, implants, injectables, combined&#xD;
             oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised&#xD;
             partner. Male subjects (surgical history of bilateral vasectomy excluded) with a&#xD;
             partner of child bearing potential must be willing to use adequate and highly&#xD;
             effective methods of birth control throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable condition of the primary disease of chronic pain, which, in the opinion of&#xD;
             the investigator, would complicate the subject's participation in the study (e.g.&#xD;
             require initiation of new medication).&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including drug allergies).&#xD;
&#xD;
          -  History of seizures or at risk (i.e. head trauma, epilepsy in family, anamnesis,&#xD;
             unclear loss of consciousness).&#xD;
&#xD;
          -  Any history of frequent nausea or emesis regardless of aetiology.&#xD;
&#xD;
          -  Malignancy or a history of malignancy.&#xD;
&#xD;
          -  History of orthostatic hypotension.&#xD;
&#xD;
          -  Subjects who have any medical or surgical conditions that might interfere with&#xD;
             transdermal absorption, distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          -  Positive results for Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies&#xD;
             (HCV Ab), human immunodeficiency virus antibodies (HIVAb).&#xD;
&#xD;
          -  Urine screening before study is positive for opioids, barbiturates, amphetamines,&#xD;
             cocaine metabolites, methadone, benzodiazepines, phencyclidine, methamphetamine, or&#xD;
             cannabinoids or alcohol breath test is positive.&#xD;
&#xD;
          -  Subjects who have a current or past (within 5 years) history of substance or alcohol&#xD;
             abuse, or subjects who, in the opinion of the investigator or the sub-investigator,&#xD;
             have demonstrated addictive or substance abuse behaviors. Alcohol abuse is defined as&#xD;
             regular alcohol consumption exceeding 14 drinks/week (1 drink = 150 mL of wine or 360&#xD;
             mL of beer or 45 mL of hard liquor).&#xD;
&#xD;
          -  Consumption of alcoholic beverages within 48 hours before patch application, and / or&#xD;
             refusal to abstain from alcohol throughout the study until at least 48 hours after&#xD;
             patch removal.&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 5&#xD;
             cigarettes per day.&#xD;
&#xD;
          -  Use of any medicinal product which inhibits CYP3A4 (e.g. troleandomycin, ketoconazole,&#xD;
             gestodene, etc) or induces CYP3A4 (e.g. glucocorticoids, barbiturates, rifampicin,etc)&#xD;
             within 4 weeks prior to first patch administration.&#xD;
&#xD;
          -  Subjects who are currently taking tricyclic antidepressants or have used tricyclic&#xD;
             antidepressants within 4 weeks prior to the first patch administration.&#xD;
&#xD;
          -  Subjects taking monoamine oxidase (MAO) inhibiters within the past 14 days prior to&#xD;
             the first patch administration&#xD;
&#xD;
          -  Subjects taking any opioid drug within the past 14 days prior to the first patch&#xD;
             administration.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs, vitamins and dietary supplements within&#xD;
             7 days prior to the first patch administration. As an exception, acetaminophen could&#xD;
             have been used at doses of ≤1 g/day.&#xD;
&#xD;
          -  Subjects who participated in a clinical research study involving a new chemical entity&#xD;
             or an experimental drug within 30 days prior to the screening visit. Concurrent&#xD;
             enrolment in another clinical trial is not permitted unless the sole purpose of the&#xD;
             other trial is for collection of long-term follow-up/survival data.&#xD;
&#xD;
          -  Donated 400 mL or more of blood or blood products within 3 months prior to the start&#xD;
             of the study.&#xD;
&#xD;
          -  Screening sitting blood pressure (BP) ≥140 mm Hg (systolic) or ≥ 90 mm Hg (diastolic),&#xD;
             following at least 5 minutes of rest. If BP is ≥140 mm Hg (systolic) or ≥ 90 mm Hg&#xD;
             (diastolic), the BP should be repeated two more times and the average of the three BP&#xD;
             values should be used to determine the subject's eligibility.&#xD;
&#xD;
          -  12-lead ECG demonstrating QTc&gt;450 msec or a QRS interval &gt;120 msec at Screening. If&#xD;
             QTc exceeds 450 msec, or QRS interval exceeds 120 msec, the ECG should be repeated two&#xD;
             more times and the average of the three QTc or QRS interval values should be used to&#xD;
             determine the subject's eligibility.&#xD;
&#xD;
          -  Subjects who have history of hypersensitivity to opioid analgesic formulations.&#xD;
&#xD;
          -  Subjects who have history of hypersensitivity to naltrexone.&#xD;
&#xD;
          -  Subjects who have history of hypersensitivity to transdermal delivery system or patch&#xD;
             adhesives.&#xD;
&#xD;
          -  Subjects with any potential dermatological disorder at a patch application site, e.g.&#xD;
             previous and/or current unhealed extensive dermal damage in the area where the patch&#xD;
             will be applied (e.g. dermatitis, burns, tattoos, scarring of the skin)&#xD;
&#xD;
          -  Subjects who could not discontinue therapy that involved direct heat sources (e.g.&#xD;
             heat lamps, electric blankets, heating pads or heated water beds) for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Subjects with hairy areas who could not, or would not, cut the hair at the patch site&#xD;
             for proper placement of the patch&#xD;
&#xD;
          -  Special diets such as caffeine or xanthine-containing foods and beverages (including&#xD;
             pitaya fruit, mango, grapefruit, coffee, tea, cola, chocolate, grapefruit juice, etc.)&#xD;
             should be taken within 48 hours before patch application or during the study.&#xD;
&#xD;
          -  Subjects who have difficulty swallowing tablets.&#xD;
&#xD;
          -  Subjects who cannot tolerate venipuncture, or subjects who have difficulty in&#xD;
             collecting blood, or subjects who have a history of fainting at the sight of blood or&#xD;
             needles.&#xD;
&#xD;
          -  Unwilling or suspected of not being able to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenping Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The affiliated hospital of Liaoning University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Di Yang, Bachelor</last_name>
    <phone>86 10 65636798</phone>
    <email>Di.Yang@mundipharma.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rongna A, Master</last_name>
    <phone>86 10 65636885</phone>
    <email>Rongna.A@mundipharma.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenping Wang, Doctor</last_name>
      <phone>86 24 31961971</phone>
      <email>wangwenping@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03975010/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

